Novartis Announces $12bn Avidity Biosciences Acquisition
Kirkland & Ellis is advising Avidity Biosciences with a team that joined the firm just this summer, as Swiss pharma giant Novartis announces plans to acquire the San Diego-based RNA therapeutics developer for a total of $12bn, with Covington & Burling advising Novartis.
The transaction is due to complete in the first half of 2026, with Novartis taking the group’s Antibody Oligonucleotide Conjugates (AOCs) platform for RNA therapeutics, as well as three late-stage neuroscience programs for neuromuscular diseases.
No direct quotes available in the given text.
Author's summary: Novartis acquires Avidity Biosciences for $12bn.
More News
- Australian government bans Dutch volleyball rapist
- From decline to renewal: Why leadership still matters
- Logistics Horizon Scanner: October 2025
- Venture Capital, Moonshots, and AI: The 2025 Tech Soap Opera
- Apple says US passport digital IDs are coming to Wallet 'soon' | TechCrunch
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- How businesses can implement Zero Waste practices
- Australian government bans Dutch volleyball rapist
- The AI Gender Gap Paradox (SSIR)